Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 24192207)

1.

Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study.

Burge R, Shen W, Naegeli AN, Alam J, Silverman S, Gold DT, Shih T.

Health Qual Life Outcomes. 2013 Nov 5;11:189. doi: 10.1186/1477-7525-11-189.

2.

Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures.

Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J.

J Bone Miner Res. 2000 Jul;15(7):1384-92.

PMID:
10893688
3.

The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study.

Silverman SL, Minshall ME, Shen W, Harper KD, Xie S; Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study.

Arthritis Rheum. 2001 Nov;44(11):2611-9.

PMID:
11710717
4.

Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures.

Oleksik AM, Ewing S, Shen W, van Schoor NM, Lips P.

Osteoporos Int. 2005 Aug;16(8):861-70. Epub 2004 Nov 19.

PMID:
15558238
5.

Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study.

Yoh K, Hamaya E, Urushihara H, Iikuni N, Yamamoto T, Taketsuna M, Miyauchi A, Sowa H, Tanaka K.

Curr Med Res Opin. 2012 Nov;28(11):1757-66. doi: 10.1185/03007995.2012.736860. Epub 2012 Oct 26.

PMID:
23035693
6.

Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial.

Silverman S, Viswanathan HN, Yang YC, Wang A, Boonen S, Ragi-Eis S, Fardellone P, Gilchrist N, Lips P, Nevitt M, Palacios Gil-Antuñano S, Pavelka K, Revicki D, Simon J, Macarios D, Siris ES.

Osteoporos Int. 2012 Apr;23(4):1361-9. doi: 10.1007/s00198-011-1720-0. Epub 2011 Jul 19.

PMID:
21769664
7.

Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study.

Guillemin F, Martinez L, Calvert M, Cooper C, Ganiats T, Gitlin M, Horne R, Marciniak A, Pfeilschifter J, Shepherd S, Tosteson A, Wade S, Macarios D, Freemantle N.

Osteoporos Int. 2013 Dec;24(12):3001-10. doi: 10.1007/s00198-013-2408-4. Epub 2013 Jun 11.

8.

The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.

Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, Grassi W; Italian Multicentre Osteoporotic Fracture Study Group.

J Rheumatol. 2007 Jul;34(7):1551-60. Epub 2007 May 15.

PMID:
17516618
9.

[Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].

Rosa J, Vanuga P, Payer J, Svobodník A.

Vnitr Lek. 2008 Mar;54(3):217-9, 221-4. Czech.

PMID:
18522288
10.
12.

Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.

Adachi JD, Lyles KW, Colón-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS.

Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20.

PMID:
21249332
13.

Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.

Ljunggren Ö, Barrett A, Stoykov I, Langdahl BL, Lems WF, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Karras D, Marin F.

BMC Musculoskelet Disord. 2013 Aug 22;14:251. doi: 10.1186/1471-2474-14-251.

14.

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.

Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL.

Bone. 2007 Apr;40(4):843-51. Epub 2006 Dec 19.

PMID:
17182297
16.

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators.

J Bone Miner Res. 2005 Sep;20(9):1514-24. Epub 2005 May 16.

PMID:
16059623
17.

Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.

Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH.

J Bone Joint Surg Am. 2009 Jun;91(6):1329-38. doi: 10.2106/JBJS.H.01030.

PMID:
19487509
18.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819
19.

Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study.

Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X; OPTIMA study investigators.

Osteoporos Int. 2006;17(5):664-71. Epub 2005 Dec 31.

PMID:
16437191
20.

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD.

Bone. 2003 Oct;33(4):522-32.

PMID:
14555255
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk